- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01429194
The ACE Follow-up Study
Continuation of Follow-up for Patients Who Were Previously Enrolled in the Clinical Study: "Open Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity - (Protocol 11-03)."
The Articulating Circular Endoscopic (ACE) Stapler is an investigational system using endoscopic guidance to trans-orally place plications in the stomach in obese subjects to reduce volume and expansion of the fundus and greater curve to abate hunger as part of a supervised weight reduction program.
The primary objective of this study is to perform an evaluation of the safety of the plication procedure.
The secondary objective of this study is to evaluate the preliminary efficacy of the ACE Stapler for the treatment of obesity over a 24 month follow-up period.
Study Overview
Detailed Description
This study was originally sponsored by BaroSense, Inc (protocol 11-03). 69 subjects were enrolled and treated as part of the study at 6 centers in 4 countries outside the United States. On April 30, 2013 BaroSense Inc went out of business and the study was terminated with all participating centers' Ethics Committees. At the point of study termination, all patients were in the middle of post procedure follow-up.
Boston Scientific has since acquired the technology and study and will re-initiate follow-up to 24 months in order to collect data to support the original safety and efficacy endpoints of the protocol. Only the 69 subjects previously enrolled and treated in BaroSense's protocol 11-03 will be eligible for participation in the Boston Scientific continued follow-up study ("The ACE Follow-up Study" protocol 90891629). The Boston Scientific protocol will be approved by participating centers' Ethics Committees and patients who choose to participate in The ACE Follow-up Study will need to sign a new, Ethics Committee Approved, informed consent form.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Autonoma de Bueno Aires, Argentina, CP 1118
- Hospital Aleman / Programa de Unidades Bariátricas
-
Mendoza, Argentina, 290
- Hospital Italiano de Mendoza / Clinica Quirugica S. A.
-
-
-
-
-
Quebec, Canada, G1V 4G5
- University Institute of Cardiology and Pulmonary Medicine of Quebec
-
-
-
-
-
Tel-Aviv, Israel, 64234
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Amsterdam, Netherlands, 110AZ
- Amsterdam Medical Center
-
Maastricht, Netherlands, 6202
- University Hospital Maastricht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject, male or female, is age 18 to 50 years of age.
- Subject must be able to understand and be willing to sign an informed consent document.
- Subject must be willing and able to participate in all aspects of the study and agree to comply with all study requirements for the duration of the study. This includes availability of reliable transportation and sufficient time to attend all follow-up visits.
- Subject has a BMI of 40 - 45 or 30 to 39.9 plus one or more co-morbid diseases expected to improve with weight loss, including but not limited to hypertension, dyslipidemia, obstructive sleep apnea, or diabetes mellitus.
- Subject must be fully ambulatory, without chronic reliance on walking aids such as crutches, walkers or a wheelchair.
- Subject must be of sufficient and stable medical health, as evaluated by the Principal Investigator.
- Subject must have a primary care physician that will manage the subject for any co-morbid conditions throughout the study.
- Subject must have failed standard obesity therapy of diet, exercise, behavior modification, and pharmacologic agents either alone or in combination, as assessed by an interview with a member of the study team at baseline.
- Subject agrees to refrain from any type of reconstructive surgery that may affect body weight such as mammoplasty or abdominal lipoplasty or liposuction, during the trial.
Exclusion Criteria:
- Subject has history of/or signs and/or symptoms of gastro-duodenal ulcer disease.
- Subject has poorly controlled diabetes as indicated by the lack of stable diabetes medications and doses over the last month, or has a history of diabetes for greater than 10 years.
- Subject has had significant weight loss in the last 3 months, or between baseline and the study procedure.
- Subject has a history or is diagnosed with eating disorders.
- Subject has history of peptic ulcer and tests positive for H. pylori, unless treated before the procedure.
- Subject has symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease.
- Subject has pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD), pneumonia or cancer.
- Subject has significant esophageal disease including Zenker's diverticulum, grade 3-4 reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal diverticulum, dysphagia, achalasia, or symptoms of dysmotility.
- Subject is observed during EGD to have heavily scarred, malignant or poor quality/friable tissue in areas of the stomach where plications are to be placed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACE procedure
ACE procedure for the treatment of obesity
|
The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: Enrollment through 24 months post-procedure.
|
The primary safety analysis will assess the occurrence and procedure relatedness of the following events:
|
Enrollment through 24 months post-procedure.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent excess weight loss
Time Frame: Procedure through 24 months post-procedure
|
Percent excess weight loss (%EWL), defined as: (preoperative weight-current weight)/(preoperative weight - ideal weight) *100, where ideal weight is the weight that would correspond to a BMI of 25 based on the subject's height. Relative to weight at the procedure visit. |
Procedure through 24 months post-procedure
|
Total weight lost (kg) and percent weight lost
Time Frame: Procedure through 24 months post-procedure
|
Relative to weight at the procedure visit.
|
Procedure through 24 months post-procedure
|
Change in Body Mass Index (BMI) and percent change in BMI
Time Frame: Procedure through 24 months post-procedure
|
Relative to BMI at the procedure visit.
|
Procedure through 24 months post-procedure
|
Change in waist circumference
Time Frame: Procedure through 24 months post-procedure
|
Relative to to waist circumference at the procedure visit.
|
Procedure through 24 months post-procedure
|
Improvement in co-morbid disease(s)
Time Frame: Enrollment through 24 months post-procedure
|
Including but not limited to, improvement in vital signs and/or laboratory values.
|
Enrollment through 24 months post-procedure
|
Changes in Quality of Life
Time Frame: Enrollment through 24 months post-procedure
|
As reported on the SF-36 Quality of LIfe Questionnaire.
|
Enrollment through 24 months post-procedure
|
Changes in Feelings of Satiety
Time Frame: Enrollment through 24 months post-procedure
|
As reported on the TFEQ-R18 Three Factor Eating Questionnaire.
|
Enrollment through 24 months post-procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Simon Biron, MD, University Institute of Cardiology and Pulmonary Medicine of Quebec
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 90891629 (Other Identifier: Boston Scientific Corporation)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on ACE Stapler
-
Nanchong Central HospitalRecruitingPostoperative Complications | Operative Time | Hospital CostsChina
-
Orthopaedic Research FoundationOrthoIndyCompletedPain | Erythema | Drainage | BruisingUnited States
-
Scitech Produtos Medicos LtdaRecruiting
-
University of AlbertaCompleted
-
Ethicon Endo-SurgeryCompletedExcision of KidneyUnited States
-
Ethicon Endo-SurgeryCompletedNon Small Cell Lung CancerUnited States
-
St. Joseph's Healthcare HamiltonNot yet recruiting
-
AesDex, LLCUnknownLobectomy | SegmentectomyUnited Kingdom
-
Russian Society of Colorectal SurgeonsI.M. Sechenov First Moscow State Medical University; Meril Life Sciences Pvt...UnknownRectal Neoplasms | Anastomotic Leak | Anastomotic Stenosis | Anastomotic Complication | Anastomosis | Anastomotic Haemorrhage | Staple MisfireRussian Federation